Is Acumen Pharmaceuticals, Inc. (ABOS) a Buy, Sell, or Hold?
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$2.22 USD
-$0.31 (-12.25%)
- Volume
- 674.38K
- Average Volume
- 450.32K
- Market Capitalization
- $134.47M
- P/E Ratio
- -1.19
- Dividend Yield
- 0.00%
- Price Target
- $7.00
- Year High
- $3.60
- Year Low
- $1.19
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.55
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Daniel J. O'Connell |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ABOS |
| CUSIP | 00509G209 |
| CIK | 0001576885 |
| Web | https://acumenpharm.com |
| Phone | 434 297 1000 |
| Currency | USD |
| Employees | 61 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.36 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.55 |
| Quick Ratio | 4.55 |
| Cash Ratio | 1.77 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.67 |
| Price / Cash Flow | -1.27 |
| Price / Book | 1.60 |
Price Target and Rating
| Average Stock Price Forecast | $7.00 |
| High Stock Price Forecast | $7.00 |
| Low Stock Price Forecast | $7.00 |
| Forecast Upside/Downside | -68.29% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2 |
| Trailing P/E Ratio | -1.19 |
| PEG Ratio | 1.35 |
| P/E Growth | 1.35 |
| Net Income | $-121.34M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -123.07% |
| Return on Assets | -84.77% |
Financials Score
| AltmanZ Score | -4.58 |
| Piotroski Score | 2.00 |
| Working Capital | 103.86M |
| Total Assets | 133.63M |
| Ebit | -109.01M |
| Market Cap | 159.91M |
| Total Liabilities | 46.15M |
Poll Results
About Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia. ...
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy
2026-07-15 13:01:12
Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
2026-07-15 10:40:48
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
2026-07-15 07:30:00
NEWTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new findings presented at the Alzheimer's Association International Conference (AAIC®) 2026 in London. Following collaboration with JCR Pharmaceuticals Co., Ltd. (JCR) on EBD candidate development, studies demonstrated improved brain penetration of anti-AβO antibodies through transferrin receptor-mediated delivery across both mouse and non-human primate models. Additionally, research from early symptomatic AD patients highlighted the lived experience among ALTITUDE-AD trial participants and their study partners.
2026-07-07 07:30:00
NEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present three key studies at the upcoming Alzheimer's Association International Conference (AAIC®) 2026 in London. Shared in one oral and two poster presentations, the data highlight Acumen's progress with JCR Pharmaceuticals (JCR), in developing next generation therapeutics through Enhanced Brain Delivery (EBD) technology and expanding the field's understanding of early symptomatic AD through the patient lens. The conference will be held July 12-15, 2026, both in-person and online.
2026-06-17 12:30:00
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development in the treatment of Alzheimer's disease (AD), enabled by JCR's proprietary blood-brain barrier (BBB)-penetrating technology platform, J-Brain Cargo®
2026-06-16 07:30:00
ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under its license agreement with JCR Pharmaceuticals EBD technology represents the only anti-amyloid oligomer program combining a validated blood-brain barrier-penetrating technology with a therapeutic antibody tested in the clinic Acumen's EBD candidates are designed to achieve higher brain penetration with potential for improved safety compared to native antibodies and delivered in a stable, low volume subcutaneous administration format Investigational New Drug (IND)-enabling activities are ongoing to support IND submission in mid-2027 NEWTON, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced the nomination of two development candidates in its Enhanced Brain Delivery (EBD) program as treatments for AD.
Acumen's Late-2026 Sabirnetug Readout Is A Viable Bet
2026-05-20 07:45:03
Acumen Pharmaceuticals is a clinical-stage Alzheimer's biotech built around sabirnetug. I believe 2026 will be mostly about its upcoming Phase 2 readout. The main appeal still lies with sabirnetug, which could offer meaningful upside if Phase 2 data supports a viable path into Phase 3. As such, ALTITUDE-AD is the main swing factor, especially if iADRS slowing lands near management's target.
2026-05-14 14:20:43
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Frequently Asked Questions
-
What is the current Acumen Pharmaceuticals, Inc. (ABOS) stock price?
-
Acumen Pharmaceuticals, Inc.(NASDAQ:ABOS) stock price is $2.22 in the last trading session. During the trading session, ABOS stock reached the peak price of $3.6 while $1.19 was the lowest point it dropped to. The percentage change in ABOS stock occurred in the recent session was --12.25% while the dollar amount for the price change in ABOS stock was -$-0.31.
-
ABOS's industry and sector of operation?
-
The NASDAQ listed ABOS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ABOS?
-
Alex Braun | Vice President & Head of Investor Relations
Robyn Moxon | Associate Director of Communications
Kelly Carranza | Senior Vice President of Finance & Accounting and Corporate Controller
Grant A. Krafft | Co-Founder
William L. Klein | Co-Founder -
How many employees does ABOS have?
-
Number of ABOS employees currently stands at 61. ABOS operates from 427 Park Street, Newton, MA 22902, US.
-
Link for ABOS official website?
-
Official Website of ABOS is: https://acumenpharm.com
-
How do I contact ABOS?
-
ABOS could be contacted at phone #434 297 1000 and can also be accessed through its website. ABOS operates from 427 Park Street, Newton, MA 22902, US.
-
How many shares of ABOS are traded daily?
-
The average number of ABOS shares traded daily for last 3 months was 450.32K.
-
What is the market cap of ABOS currently?
-
The market value of ABOS currently stands at $134.47M with its latest stock price at $2.22